ADAR1 Capital Management LLC Cuts Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

ADAR1 Capital Management LLC cut its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 2.5% during the fourth quarter, HoldingsChannel reports. The firm owned 90,984 shares of the biotechnology company’s stock after selling 2,300 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Astria Therapeutics were worth $813,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new stake in Astria Therapeutics in the fourth quarter worth about $41,000. Teacher Retirement System of Texas acquired a new position in Astria Therapeutics in the 4th quarter worth approximately $91,000. New York State Common Retirement Fund lifted its position in Astria Therapeutics by 67.0% during the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 4,300 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Astria Therapeutics during the fourth quarter valued at approximately $107,000. Finally, SG Americas Securities LLC grew its position in Astria Therapeutics by 51.3% during the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 7,218 shares during the period. 98.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ATXS shares. Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Finally, JMP Securities initiated coverage on Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Astria Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $26.60.

Astria Therapeutics Stock Performance

ATXS stock opened at $4.66 on Monday. Astria Therapeutics, Inc. has a one year low of $4.62 and a one year high of $12.92. The stock has a market capitalization of $262.98 million, a P/E ratio of -2.23 and a beta of 0.68. The company has a 50 day moving average price of $6.58 and a two-hundred day moving average price of $8.91.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. Research analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current fiscal year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.